Trials / Unknown
UnknownNCT04325776
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
A Randomized, Double-blind and Imitation, Parallel-control, Multicenter Phase II Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) With Bone Metastasis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of c-met, tumor angiogenesis and tumor cell migration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL2846 | AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met. |
| DRUG | Zoledronic Acid Injection | Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors. |
Timeline
- Start date
- 2020-09-24
- Primary completion
- 2021-05-01
- Completion
- 2021-11-01
- First posted
- 2020-03-30
- Last updated
- 2020-10-12
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04325776. Inclusion in this directory is not an endorsement.